Drugs - Mechanisms II Flashcards
methylcellulose
bulk forming laxative
Desvenlafaxine
SNRI
Tiagabine
GABA reuptake inhibitor
magnesium compounds
osmotic laxatives
Gabapentin
inhibits high voltage activate Ca channels
Ketoconazole
inhibits 17-alpha hydroxylase –> decreased steroids
Imipramine
TCA –> SNRI
-azine
1st gen antipsychotics
chlorpheniramine
1st gen H1 blocker
Entacapone and tolcapone
inhibits COMT –> reduced peripheral L-DOPA degradation
Anastrozole
Aromatase inhibitor
sucralfate
binds to peptic ulcer base –> protects –> bicarb secretion reestablishes pH
Sevelamer
non-absorbable phosphate binder
Riluzolone
decreased glutamate excitotocity in ALS
doxylamine
1st gen H1 blocker
Bromocriptine
Ergot dopamine agonist
Levetiracetam
SV2A receptor blocker
Procarbazine
mechanism unknown, weak MAO inhibitor
Selegiline
Selective MAO-B inhibitor
Liraglutide
(GLP-1 analog) decrease glucagon release, decrease gastric emptying, and increase glucose dependent insulin release
Methimazole
thionamide, blocks thyroid peroxidase (teratogenic)
-raf-enib
BRAF
Conivaptan
ADH antaogonist
Afitinib
EGFR inhibitor
Acarbose
alpha-glucosidase inhibitor in brush border –> decreased absoprtion –> decreased postprandial hyperglycemia
Ketamine
NMDA antagonist
Fluoxetine
SSRI
Megestrol
Progestin
Succinylcholine
strong ACh receptor agonist –> sustained depolarization –> prevents contraction
benzodiazapenes
increase GABAa activity
Probenecid
Inhibits uric acid reabsorption in the PCT and inhibits secretion of penicillin
Sulfasalazine
combo antibacterial and anti-inflammatory (used for crohns and colitis)
Etoposide, teniposide
topoisomerase II inhibitors –> DNA degradation
SGLT2 inhibitors (-gliflozins)
block reabsorption of glucose in PCT
Finasteride
5-alpha reductase inhibitor –> decreased conversion of testosterone to DHT
Baclofen
GABAb agonist in spinal cord –> decreased spasticity
Allopurinol
xanthine oxidase inhibitor
Dabigatran
Direct factor IIa inhibitor
Carbadopa
inhibits DOPA decarboxylase –> reduced peripheral L-DOPA degradation
Levomilnacipran
SNRI
Cation exchange resins (e.g. patiromer)
bind K in colon
Argatroban
Direct factor IIa inhibitor
Venlafaxine
SNRI
Arepitant
Substance Pantagonist, blocks NK1 receptors in brain –> antiemetic
Odansetron
5-HT3 antagonist –> decreased vagal stimulation –> antiemetic
Vilazodone
Atypical antidepressant; inhibits 5-HT reuptake
Phenobarbital
increases GABAa activity
Mifepristone
anti-progestin
Selegiline and rasagiline
MAO-B inhibitor –> prevents dopamine degradation
Acetazolamide
Carbonic anhydrase inhibitor –> bicarb diuresis and alkaline urine
Sertlraline
SSRI
Metoclopramide
D2 receptor antagonist –> increased resting tone and contractility –> promotes motility and gastric emptying
Propofol
potentiates GABAa
Escitalopram
SSRI
Bisacodyl
enteric nerve stimulation –> laxative
Senna
enteric nerve stimulation –> laxative
Cyclobenzaprine
Acts mainly in brain stem to reduce spasticity
Abiraterone
inhibits 17-alpha hydroxylase –> decreased steroids
Vigabatrin
inhibits GABA transaminase –> increased GABA (black box for vision loss
Histrelin
GnRH analog (agonist when pulsatile, inhibitory when continuous)
Amoxapine
TCA –> SNRI
Nafarelin
GnRH analog (agonist when pulsatile, inhibitory when continuous)
Danazol
synthetic androgen –> partial agonist
polyethylene glycol
osmotic laxative
-curonium
competetive ACh antagonists
Torsemide
loop diuretic; inhibits Na/K/2Cl cotransporter in TAL (also Ca loss)
Alectinib
ALK inhibitor
Prasugrel
Blocks ADP receptor –> decreased expression of GpIIb/IIIa –> decreased platelet aggregation
Busulfan
alkylating agent –> cross-links DNA
Fludrocortisone
aldosterone analog with glucocorticoid effects
Teriparatide
PTH analog; pulsatile dose activates osteoblasts (used in osteoporososis)
Ruxolitinib
JAK1/2 inhibitor
Letrozole
Aromatase inhibitor
Erlotinib
EGFR inhibitor
Midazolam
facilitates GABAa (benzodiazapine)
Clomiphene
Estrogen receptor modulator; antagonist in hypothalamus –> blocks negative feedback –> increased LH and FSH –> ovulation
Butorphanol
kappa-opioid agonist and partial mu
Bisphosphonates (-dronate)
pyrophosphate analogs –> bind hydroxyapatite –> inhibit osteoclasts
GLP-1 analogs
decrease glucagon release, decrease gastric emptying, and increase glucose dependent insulin release
Carbamazapine
blocks Na channels (anti-epileptic)
Thiopental
facilitates GABAa (barbiturate)
Orlistat
inhibits gastric and pancreatic lipase –> decreased absorption of dietary fat
Spironolactone
Competitive aldosterone antagonist; K sparing Diuretic; also androgen receptor and synthesis inhibitor
Tetrabenzine
inhibits monamine transporter –> decreased dopamine (in HD)
-gliptin
DPP-4 inhibitors –> prevents GLP-1 inactivation –> decrease glucagon release, decrease gastric emptying, and increase glucose dependent insulin release
Levonorgestrel
Progestin
Loperimide
mu-opioid agonist with poor CNS penetration –> slows gut mobility
Leuprolide
GnRH analog (agonist when pulsatile, inhibitory when continuous)
Pramipexole
non-ergot dopamine agonist
dipyridamole
blocks platelet phosphodiesterase –> decreased cAMP –> decreased aggregation
Duloxetine
SNRI
Mirtazapine
Atypical antidepressant; alpha2 antagonist –> increased NE and 5-HT release; potent 5-HT2/3 antagonist; H1 antagonist
Pramlintind
Amylin analog –> decreased glucagon release and gastric emptying
bismuth
binds to peptic ulcer base –> protects –> bicarb secretion reestablishes pH
Platinum compounds
cross-link DNA
Palbociclib
CDK 4/6
Liothyronine
T3 replacement
Cochicine
binds and stabilizes tubulin –> impaired neutrophil chemotaxis
Endothelin antagonists (e.g. Bosentan)
decreased PVR
Doxorubicin
anthracyline; free radical formation, DNA intercalation, and inhibition of topoisomerase II
Suggamadex
reverses ACh receptor blockade
Memantine
NMDA antagonist –> decreased excitotoxicity in AD
-adine
2nd gen H1 blockers
Pegloticase
Recombinant uricase, converts uric acid to allantoin (more water soluble)
Flutamide and Bicalutamide
competitive inhibitor at androgen receptor
Paroxetine
SSRI
Goserelin
GnRH analog (agonist when pulsatile, inhibitory when continuous)
Bumetanide
loop diuretic; inhibits Na/K/2Cl cotransporter in TAL (also Ca loss)
Local anasthetics
bind voltage gated N channels –> block neurotransmission
Ethosuximide
Blocks thalamic T-type Ca channels (absence seizures)
Pentazocine
kappa-opioid agonist and weak mu antagonist (or partial agonist)
Ironotecan. and topotecan
topoisomerase I inhibitors –> DNA degradation
Eplerenone
Competitive aldosterone antsagonist; K sparing Diuretic
Isocarboxazid
MAO-I
Diphenhydramine
1st gen H1 blocker
-prazole
Proton pump inhibitors
Exemestane
Aromatase inhibitor
Ticlopidine
Blocks ADP receptor –> decreased expression of GpIIb/IIIa –> decreased platelet aggregation
buspirone
partial 5HT agonist (used for anxiety)
Democlocycline
interferes with ADH signalling
Edoxaban
Direct factor Xa inhibitor
Dimenhydrinate
1st gen H1 blocker
Clopidogrel
Blocks ADP receptor –> decreased expression of GpIIb/IIIa –> decreased platelet aggregation
Citalopram
SSRI
Cinacalcet
Sensitizes CaSR in parathryoid to Ca –> decrease PTH
Dextromethorphan
antagonizes NMDA receptors, mild opioid in excess
Febuxostat
Xanthine oxidase inhibitor
Lamotrigine
Blocks voltage gated Na channels, inhibits glutamate release
Bivalirudin
Direct factor IIa inhibitor
Clomipramine
TCA –> SNRI
Ethacrynic acid
non-sulfa loop diuretic (no allergy but more ototoxicity)
Levothyroxine
T4 replacement
Hydrochlorothiazide
Thiazide diuretic; inhibits NaCl reabsorption in early DCT (decrease Ca excretion and diluting capacity)
Zileuton
5-Lipoxygenase inhibitor –> decreased Leukotrienes
Ticagrelor
Blocks ADP receptor –> decreased expression of GpIIb/IIIa –> decreased platelet aggregation
Tranylcypromine
MAO-I
Metolazone
Thiazide diuretic; inhibits NaCl reabsorption in early DCT (decrease Ca excretion and diluting capacity)
Psyllium
bulk forming laxative
Desipriamine
TCA –> SNRI
Amantadine
increased dopamine release and decrease uptake
-sartan
ARBs
Pseudoephedrine
alpha agonist in nasal mucosa
Bleomycin
free radicals –> DNA strand breaks
Amitriptyline
TCA –> SNRI
Chlorthalidone
Thiazide diuretic; inhibits NaCl reabsorption in early DCT (decrease Ca excretion and diluting capacity)
Phenytoin
Blocks Na channels (zero order kinetics)
Sumatriptan
5HT agonist –> inhibits trigeminal nerve activation (treats headaches)
Cell cycle specificity of antimetabolites
S phase
Trazadone
Atypical antidepressant; blocks 5-HT2, alpha1 and H1
norethindrone
Progestin
-glinide
Meglitinides, like sulfonylureas, close K channels –> depolarize –> Ca influx –> inulin release
Misoprostol
PGE1 analog –> increased gastric mucous barrier and decreased acid production
Vortioxetine
Atypical antidepressant, inhibits 5HT reuptake
Topiramate
Blocks Na channels, increases GABA action
Tramadol
weak opioid and SNRI
Desmopressin
ADH analaog
Bupropion
Atypical antidepressant; inhibits NE and D uptake
Milnacipran
SNRI
Pomozide
1st gen antipsychotic
Tamoxifen
Estrogen receptor modulator; Antagonist in breast, partial agonist in uterus and bone
Cilostazol
blocks platelet phosphodiesterase –> decreased cAMP –> decreased aggregation
Degarelix
GnRH antagonist (no start up flare –> good for cancer)
octreotide
somatostatin analog
Nitrosoureas (-mustine)
alkylating agent –> cross-links DNA (cross BBB)
Furosemide
loop diuretic; inhibits Na/K/2Cl cotransporter in TAL (also Ca loss)
Tolvaptan
ADH antagonist
Propylthiouracil
thionamide, blocks thyroid peroxidase and T4 –> T3 conversion
Cimetidine
H2 blocker –> decreased H+ secretion by parietal cells
Leflunomide
reversibly inhibits dihydroorotate dehydrogenase –> prevents pyrimidine synthesis –> suppresses T cell proliferation
Abciximab
blocks GpIIb/IIIa on activated platelets (fibrinogen receptor)
Doxepin
TCA –> SNRI
ulipristal
anti-progestin
Aliskiren
direct Renin inhibitor
Varenicline
Atypical antidepressant; nicotinic Ach receptor partial agonist (smoking cessation)
Celoxib
Selective COX-2 inhibition (spares GI lining unlike other NSAIDS)
Raloxifene
Estrogen receptor modulator; Antagonist in breast and uterus, partial agonist in bone –> used for osteoperosis
Aripiprazole
2nd gen (atypical) antipsychotic (partial agonist though)
cyclophosphamide
alkylating agent –> cross-links DNA
Amiloride
Block Na channels in cortical CT; K sparing diuretic
-apine and -idone
2nd gen (atypical) antipsychotics
Exantide
(GLP-1 analog) decrease glucagon release, decrease gastric emptying, and increase glucose dependent insulin release
Fluvoxamine
SSRI
etonogestrel
Progestin
Gefitinib
EGFR inhibitor
lactulose
osmotic laxative
Miglitol
alpha-glucosidase inhibitor in brush border –> decreased absoprtion –> decreased postprandial hyperglycemia
Phenelzine
MAO-I
Rivaroxaban
Direct factor Xa inhibitor
Docusate
emmolient laxative (incorporation of water and fat)
Ropinorole
non-ergot dopamine agonist
Apixaban
Direct factor Xa inhibitor
Nizatidine
H2 blocker –> decreased H+ secretion by parietal cells
phenylephrine
alpha agonist in nasal mucosa
haloperidol
1st gen antipsychotic
Mestranol
estrogen
Famotidine
H2 blocker –> decreased H+ secretion by parietal cells
Valproic Acid
Na channel activation, inhibits GABA transaminase –> increased GABA
Nortriptyline
TCA –> SNRI
-pril
ACE inhibitors
Triamterine
Block Na channels in cortical CT; K sparing diuretic